Survivorship after Hodgkin lymphoma and the right to be forgotten
- PMID: 39007329
- DOI: 10.1097/CCO.0000000000001072
Survivorship after Hodgkin lymphoma and the right to be forgotten
Abstract
Purpose of review: The significantly improved survivorship in Hodgkin lymphoma is fraught with challenges, including persistent symptoms, secondary health complications, and socio-professional obstacles. This review highlights the need for comprehensive survivorship care plans that include detection of relapse, assessment of long-term side effects, screening for secondary cancers, psychological support, and assistance with socio-professional integration.
Recent findings: Cardiovascular diseases, secondary malignancies and other associated risks remains an important problem related to the effective treatment of patients with Hodgkin lymphoma. Furthermore, fertility concerns and endocrine disorders remain prevalent issues posttreatment. An optimal evaluation of the risks before and after treatment is essential to reduce the impact of these side effects on quality of life. Addressing the socio-professional reintegration of survivors, the concept of the 'Right to be forgotten' emerges as a critical consideration. This principle seeks to eliminate discrimination against cancer survivors in accessing financial services and aims for legislative changes to ensure that past cancer diagnosis does not unfairly affect survivors' futures. Implementation of this 'Right to be forgotten' in the legislature, is currently underway in European countries.
Summary: The focus of survivorship care has shifted towards the holistic management of these long-term outcomes. Quality of life for Hodgkin lymphoma survivors is affected by various treatment-related factors, with evidence suggesting that physical, psychological and socio-professional domains remain impacted years after treatment.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
References
-
- Shapiro CL. Cancer survivorship. N Engl J Med 2018; 379:2438–2450.
-
- European Commission: A Cancer Plan for Europe [cited 13 March 2023]. Available at: https://commission.europa.eu/strategy-and-policy/priorities-2019-2024/pr... . [Accessed 13 March 2024].
-
- Conquering Cancer: mission possible: interim report of the mission board for cancer (European Commission) [cited 10 March 2023]. Available at: https://op.europa.eu/en/web/eu-law-and- publications/publication-detail/-/publication/d0235612-b68a-11ea-bb7a-01aa75ed71a1 .
-
- Denlinger CS, Sanft T, Moslehi JJ, et al. NCCN guidelines insights: survivorship, version 2.2020. J Natl Compr Cancer Netw 2020; 18:1016–1023.
-
- The surveillance, epidemiology, and end results (SEER). [cited 13 February 2023]. Available at: https://seer.cancer.gov/statfacts/html/hodg.html .
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
